[go: up one dir, main page]

RS50360B - Farmaceutske formulacije derivata platine - Google Patents

Farmaceutske formulacije derivata platine

Info

Publication number
RS50360B
RS50360B YUP-597/04A YUP59704A RS50360B RS 50360 B RS50360 B RS 50360B YU P59704 A YUP59704 A YU P59704A RS 50360 B RS50360 B RS 50360B
Authority
RS
Serbia
Prior art keywords
pharmaceutically acceptable
lactic acid
oxaliplatin
pharmaceutical formulations
platinum derivative
Prior art date
Application number
YUP-597/04A
Other languages
English (en)
Inventor
Sara Lauria
Alessandro Martini
Cristina Ciocca
Original Assignee
Pharmacia Italia S.P.A.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21744006&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS50360(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia Italia S.P.A., filed Critical Pharmacia Italia S.P.A.,
Publication of YU59704A publication Critical patent/YU59704A/sh
Publication of RS50360B publication Critical patent/RS50360B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Stabilna formulacija rastvora oksaliplatina naznačena time, što sadrži formulaciju odabranu iz grupe koja se sastoji od: (a) oksaliplatina , efiksane stabilizujuće količine mlečne kiseline i farmaceutski prihvatljiv nosač; (b)oksaliplatina , efiksane stabilizujuće količine farmaceutski prihvatljive soli mlečne kiseline i farmaceutski prihvatljiv nosač i; (c)oksaliplatina , efiksane stabilizujuće količine mlečne kiseline i farmaceutski prihvatljivu so mlečne kiseline i farmaceutski prihvatljiv nosač.Prijava sadrži još 27 zavisnih patentnih zahteva.
YUP-597/04A 2001-12-06 2002-11-22 Farmaceutske formulacije derivata platine RS50360B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/010,122 US6476068B1 (en) 2001-12-06 2001-12-06 Platinum derivative pharmaceutical formulations

Publications (2)

Publication Number Publication Date
YU59704A YU59704A (sh) 2006-08-17
RS50360B true RS50360B (sr) 2009-11-10

Family

ID=21744006

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-597/04A RS50360B (sr) 2001-12-06 2002-11-22 Farmaceutske formulacije derivata platine

Country Status (42)

Country Link
US (3) US6476068B1 (sr)
EP (1) EP1453517B1 (sr)
JP (1) JP2005515202A (sr)
KR (1) KR100941210B1 (sr)
CN (1) CN100540006C (sr)
AP (1) AP1760A (sr)
AR (1) AR037629A1 (sr)
AT (1) ATE317260T1 (sr)
AU (1) AU2002352105B2 (sr)
BR (1) BR0214757A (sr)
CA (1) CA2468916C (sr)
CO (1) CO5580776A2 (sr)
CR (1) CR7362A (sr)
CY (1) CY1105608T1 (sr)
DE (1) DE60209145T2 (sr)
DK (1) DK1453517T3 (sr)
EA (1) EA008090B1 (sr)
EC (1) ECSP045140A (sr)
ES (1) ES2258661T3 (sr)
GE (1) GEP20063895B (sr)
HK (1) HK1072002A1 (sr)
HR (1) HRP20040514A2 (sr)
HU (1) HUP0402217A3 (sr)
IL (2) IL162348A0 (sr)
IS (1) IS2580B (sr)
MA (1) MA27153A1 (sr)
ME (1) MEP10408A (sr)
MX (1) MXPA04005423A (sr)
MY (1) MY134422A (sr)
NO (1) NO330159B1 (sr)
NZ (1) NZ533383A (sr)
OA (1) OA12739A (sr)
PL (1) PL206755B1 (sr)
PT (1) PT1453517E (sr)
RO (1) RO121509B1 (sr)
RS (1) RS50360B (sr)
SI (1) SI21493A (sr)
TN (1) TNSN04104A1 (sr)
TW (1) TW200409640A (sr)
UA (1) UA77728C2 (sr)
WO (1) WO2003047587A1 (sr)
ZA (1) ZA200404525B (sr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003004505A1 (en) * 2001-07-02 2003-01-16 Debiopharm S.A. Oxaliplatin active substance with a very low content of oxalic acid
CA2388352A1 (en) * 2002-05-31 2003-11-30 Voiceage Corporation A method and device for frequency-selective pitch enhancement of synthesized speed
US20040022842A1 (en) * 2002-06-03 2004-02-05 Mebiopharm Co., Ltd. Liposome preparations containing oxaliplatin
DE10314377A1 (de) * 2003-03-28 2004-10-07 Stada Arzneimittel Ag Gebrauchsfertige Oxaliplatin-Lösungen
GB2441445B (en) * 2003-08-28 2008-04-23 Mayne Pharma Ltd Acid containing oxaliplatin formulation
CN101703467A (zh) * 2003-08-28 2010-05-12 梅恩医药有限公司 含有酸的奥沙利铂制剂
KR101167573B1 (ko) * 2003-11-07 2012-07-30 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 개선된 약학적 성질을 갖는 퀴놀리논 화합물의 약학적으로허용가능한 염
US7795205B2 (en) * 2004-04-12 2010-09-14 Canyon Pharmaceuticals, Inc. Methods for effecting regression of tumor mass and size in a metastasized pancreatic tumor
CA2569739C (en) * 2004-06-09 2011-11-29 Katsuhisa Koizumi Antitumor effect potentiator, antitumor preparation, and method for treating cancer
CA2573747A1 (en) * 2004-07-12 2006-03-02 Sicor, Inc. Cis-diiodo-(trans-l-1,2-cyclohexanediamine) platinum (ii) complex and p rocesses for preparing high purity oxaliplatin
US20060063833A1 (en) * 2004-09-22 2006-03-23 Edgar Schridde Ready-to-use oxaliplatin solutions
US20060063720A1 (en) * 2004-09-22 2006-03-23 Edgar Schridde Oxaliplatin solution concentrate
DE102004052877B4 (de) * 2004-11-02 2008-06-19 Ebewe Pharma Ges.M.B.H. Nfg.Kg Stabile wässrige Formulierungen eines Platin-Derivats
CN1311818C (zh) * 2004-11-22 2007-04-25 山东蓝金生物工程有限公司 一种抗实体肿瘤的药物组合物
DE102004063764A1 (de) * 2004-12-29 2006-07-13 Hexal Ag Kunststoff-Flasche für Oxaliplatin
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
WO2006103691A1 (en) * 2005-03-28 2006-10-05 Dabur Pharma Ltd. Stable pharmaceutical compositions of platinum (ii) antitumour agents
NZ564144A (en) * 2005-05-13 2009-11-27 Novartis Ag Methods for treating drug resistant cancer
DE102005038347A1 (de) * 2005-08-11 2007-02-15 Hexal Ag Herstellung einer Oxaliplatin-Lösung und Behälter sowie Behälter-Set mit der Lösung
WO2007029268A2 (en) * 2005-09-05 2007-03-15 Dabur Pharma Limited Stable oxaliplatin formulation
CA2627544C (en) * 2005-11-29 2015-07-07 Novartis Ag Formulations of quinolinones for the treatment of cancer
US20090076139A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched oxalplatin
US20100267824A1 (en) * 2007-11-12 2010-10-21 Intas Pharmaceuticals Limited Stable oxaliplatin composition for parenteral administration
EP2259776A4 (en) * 2008-02-29 2011-03-16 Eagle Pharmaceuticals Inc USEFUL TOPOTECAN SOLUTIONS
TW201021855A (en) * 2008-11-13 2010-06-16 Taigen Biotechnology Co Ltd Lyophilization formulation
CA2774669C (en) * 2009-09-21 2017-12-19 Jw Pharmaceutical Corporation Oxaliplatin nanoparticles and method for preparing same
WO2012006101A2 (en) 2010-06-28 2012-01-12 The General Hospital Corporation Blood substitutes and uses thereof
CN102274171A (zh) * 2011-08-04 2011-12-14 上海希迪制药有限公司 一种奥沙利铂注射剂
US10022326B2 (en) 2012-07-18 2018-07-17 Onyx Therapeutics, Inc. Liposomal compositions of epoxyketone-based proteasome inhibitors
JP5929607B2 (ja) * 2012-08-06 2016-06-08 ニプロ株式会社 オキサリプラチン製剤
CN102885765B (zh) * 2012-10-25 2013-11-06 哈药集团生物工程有限公司 一种盐酸伊立替康注射液及其制备方法
US10098813B2 (en) * 2014-09-03 2018-10-16 Sun Pharmaceutical Industries Limited Perfusion dosage form
KR101683635B1 (ko) * 2014-12-29 2016-12-09 가천대학교 산학협력단 락테이트 금속염을 포함하는 암 치료용 약학 조성물
EP4011377B1 (en) * 2015-02-13 2024-10-23 Sun Pharmaceutical Industries Ltd Intravenous infusion dosage form comprising pemetrexed
KR102293907B1 (ko) * 2015-06-30 2021-08-26 한미약품 주식회사 이리노테칸 함유 경구용 고형제제 및 그 제조방법
EP3413862B8 (en) 2016-02-09 2024-03-13 Sun Pharmaceutical Industries Ltd. Perfusion system
WO2018087720A1 (en) 2016-11-14 2018-05-17 Novartis Ag Compositions, methods, and therapeutic uses related to fusogenic protein minion
BR112020013111A2 (pt) 2018-01-12 2020-12-01 Metimedi Pharmaceuticals Co., Ltd. métodos de tratamentos da doença de alzheimer, de esclerose múltipla, de pulpite, de doença inflamatória intestinal e de lesão medular
KR101998246B1 (ko) 2018-08-22 2019-07-10 주식회사 메타파인즈 금속이온에 결합된 이온화합물을 포함하는 암 치료용 약학 조성물

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6041077B2 (ja) 1976-09-06 1985-09-13 喜徳 喜谷 １，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体
US5041578A (en) * 1988-11-22 1991-08-20 Board Of Regents, The University Of Texas System Water soluble 1,2-diaminocyclohexane platinum (IV) complexes as antitumor agents
WO1993009782A1 (en) 1991-11-15 1993-05-27 Smithkline Beecham Corporation Combination chemotherapy
JPH0776230B2 (ja) 1992-01-13 1995-08-16 田中貴金属工業株式会社 白金化合物の製造方法
JP2673331B2 (ja) 1993-01-12 1997-11-05 田中貴金属工業 株式会社 光学的に高純度なシス―オキザラート（トランス―１―１，２―シクロヘキサンジアミン）白金（▲ｉｉ▼）
JPH06287021A (ja) 1992-04-22 1994-10-11 Tanaka Kikinzoku Kogyo Kk 光学活性な白金錯化合物の光学的分割方法
WO1994012193A1 (fr) 1992-11-24 1994-06-09 Debiopharm S.A. Combinaison de cisplatine avec l'oxaliplatine
EP0835657B1 (en) * 1992-11-27 2004-08-25 Mayne Pharma (USA) Inc. Stable injectable paclitaxel composition
JP3025602B2 (ja) 1993-05-21 2000-03-27 デビオファーム エス．アー． 光学的に高純度なシス−オキザラート（トランス−ｌ−１，２−シクロヘキサンジアミン）白金（ＩＩ）錯体の製造方法
US5455270A (en) * 1993-08-11 1995-10-03 Bristol-Myers Squibb Co. Stabilized solutions of platinum(II) antitumor agents
JP3547755B2 (ja) 1994-08-08 2004-07-28 デビオファーム・エス・アー オキサリプラティヌムの医薬的に安定な製剤
ES2206478T3 (es) 1994-11-11 2004-05-16 Debiopharm S.A. Composiciones carcinostaticas que contienen cis-oxaliplatino y otra u otras sustancias carcinostaticas compatibles.
US5919816A (en) 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
DE69627641T2 (de) * 1995-02-28 2004-02-05 Kidani, Yoshinori, Fujisawa Platin(iv)-komplexe, verfahren zu ihrer herstellung und sie enthaltende carcinostatische mittel
US5776959A (en) 1995-06-05 1998-07-07 Washington University Anticonvulsant and anxiolytic lactam and thiolactam derivatives
JP3862758B2 (ja) * 1996-03-11 2006-12-27 喜徳 喜谷 二核白金錯体、その調製方法及びその錯体を含有する医薬組成物
JP3154399B2 (ja) 1996-07-04 2001-04-09 デビオファーム エス．アー． 白金化合物の製造方法
DK0929293T3 (da) 1996-08-23 2004-02-02 Sequus Pharm Inc Liposomer indeholdende en cisplatinforbindelse
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
NZ337502A (en) 1997-02-05 2001-02-23 Upjohn Co Lipid complexes and liposomes of highly insoluble platinum complexes
DK1014990T3 (da) 1997-03-07 2006-12-11 Sanofi Aventis Us Llc Antitumorkombination af 3 amino-1,2,4 benzotriazin-1,4 dioxid/paclitaxel/platin
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
GB9804013D0 (en) * 1998-02-25 1998-04-22 Sanofi Sa Formulations
CA2346564C (fr) 1998-10-14 2011-05-03 Debiopharm S.A. Conditionnement d'une preparation d'oxaliplatine
ES2206288T3 (es) 1999-08-30 2004-05-16 Debiopharm S.A. Preparacion farmaceutica estable de oxiliplatino para su administracion por via parenteral.
WO2001066102A2 (en) 2000-03-08 2001-09-13 Bristol-Myers Squibb Company Oral dosage form for administration of the combination of tegafur, uracil, folinic acid, and oxaliplatin and method of using the same
SE0003026D0 (sv) * 2000-08-25 2000-08-25 Kerstin Sunnerheim Use for conifer sapling protection

Also Published As

Publication number Publication date
WO2003047587A1 (en) 2003-06-12
MEP10408A (en) 2011-02-10
CN1612737A (zh) 2005-05-04
OA12739A (en) 2006-06-30
ECSP045140A (es) 2004-08-27
YU59704A (sh) 2006-08-17
DE60209145D1 (de) 2006-04-20
NO20042842L (no) 2004-07-05
IL162348A0 (en) 2005-11-20
NZ533383A (en) 2007-02-23
US6476068B1 (en) 2002-11-05
CA2468916A1 (en) 2003-06-12
IS7298A (is) 2004-06-03
HRP20040514A2 (en) 2004-10-31
DE60209145T2 (de) 2006-10-26
MA27153A1 (fr) 2005-01-03
AR037629A1 (es) 2004-11-17
BR0214757A (pt) 2004-09-14
KR20050058278A (ko) 2005-06-16
RO121509B1 (ro) 2007-10-30
EA008090B1 (ru) 2007-02-27
EP1453517B1 (en) 2006-02-08
AP2004003055A0 (en) 2004-06-30
HUP0402217A2 (hu) 2005-01-28
CA2468916C (en) 2009-01-20
IL162348A (en) 2010-11-30
MXPA04005423A (es) 2004-10-11
US20030109515A1 (en) 2003-06-12
IS2580B (is) 2010-02-15
ZA200404525B (en) 2005-08-15
DK1453517T3 (da) 2006-06-19
ATE317260T1 (de) 2006-02-15
UA77728C2 (en) 2007-01-15
TNSN04104A1 (fr) 2006-06-01
AU2002352105B2 (en) 2009-12-03
EP1453517A1 (en) 2004-09-08
CO5580776A2 (es) 2005-11-30
CY1105608T1 (el) 2010-12-22
PT1453517E (pt) 2006-06-30
SI21493A (sl) 2004-12-31
EA200400777A1 (ru) 2004-12-30
ES2258661T3 (es) 2006-09-01
AP1760A (en) 2007-07-18
AU2002352105A1 (en) 2003-06-17
TW200409640A (en) 2004-06-16
CR7362A (es) 2009-02-12
KR100941210B1 (ko) 2010-02-10
CN100540006C (zh) 2009-09-16
HUP0402217A3 (en) 2005-11-28
PL370254A1 (en) 2005-05-16
NO330159B1 (no) 2011-02-28
PL206755B1 (pl) 2010-09-30
JP2005515202A (ja) 2005-05-26
GEP20063895B (en) 2006-08-10
US20030109514A1 (en) 2003-06-12
MY134422A (en) 2007-12-31
HK1072002A1 (en) 2005-08-12
US6673805B2 (en) 2004-01-06

Similar Documents

Publication Publication Date Title
RS50360B (sr) Farmaceutske formulacije derivata platine
HRP20020198B1 (en) Moxifloxacin formulation containing common salt
AU2001296865A1 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
NO20011721D0 (no) N-aralkylaminotetraliner som ligander for neuropeptid Y Y5 reseptor
MY114388A (en) Multiple unit pharmaceutical preparation
YU84703A (sh) Oralni rastvor aripiprazola
DK0750618T3 (da) Oxazolidinonderivater og farmaceutiske præparater indeholdende dem
DE60204452D1 (de) Pyrazolo[1,5]pyridinderivate
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
CY1106522T1 (el) Ετepοκυκλικη ενωση και αντικαρκινικο μεσο που πepιεχει την ιδια ως δραστικο συστατικο
HUP0203028A2 (hu) Tolterodint tartalmazó gyógyszerkészítmény és alkalmazása
DK1207756T3 (da) Anvendelse af spinosad eller en formulering, der omfatter spinosad
CY1111698T1 (el) Συνδυασμος που περιλαμβανει εναν ανταγωνιστη υποδοχεα ατ1 και εναν ενισχυτη εκκρισης ινσουλινης ή εναν ευαισθητοποιητη ινσουλινης
ATE300541T1 (de) Pyrazolopyridinderivate
CY1107819T1 (el) Φαρμακευτικη διαμορφωση της ολανζαπινης
HRP20020298B1 (en) Pharmaceutical solutions of levosimendan
SE0300908D0 (sv) Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
WO2002024697A1 (fr) Composes spiro et inhibiteurs de molecules d'adhesion contenant ces composes comme ingredient actif
RS51923B (sr) So 4[[4-[[4-(2-cijanoetenil)-2,6-dimetilfenil]amino]-2- pirimidinil]amino]benzonitrila
HUP0203226A2 (hu) Hatóanyagként benzamidszármazékot tartalmazó gyógyszerkészítmény
IT1249697B (it) Composizione erbicida e procedimento per produrla.
HUP0600084A2 (en) Pharmaceutical compositions containing ascorbic acid derivatives, methods of production of the active ingredient
AU5879798A (en) Agents inhibiting progress of pterygium and postoperative recurrence of the same
HRP20070441T3 (en) Pharmaceutical combination for the treatment of spasticity and/or pain
YU82693A (sh) Farmaceutske formulacije disulfonil metana i novi disulfonil metani